Kevetrin(TM) has significant potential to be a major breakthrough in the treatment of solid tumors. !!!
Why are you confident about Kevetrin?
Ehrlich: It is because of the p53 pathway. I could go on for quite some time about how important p53 is and how many companies have researched it over the last three decades trying to understand it and find a way to repair damaged or mutated p53 in cancer. It’s aptly dubbed name of “The Guardian Angel of the Human Genome” really says it all as it is a master regulator of cell cycles. Think about it this way: It is well documented that in at least half of all cancers, p53 is mutated or damaged and not performing its duty to regulate the life cycle of a cell; most importantly, not seeing to it that cancer cells are destroyed before they can continue to split and run rampant. We appear to have something that bridges the gap between damaged p53 and the massive amount of cancer patients it affects. Now, obviously, that is the short version. It is much more complex than that as there are different scenarios that define “wild” and “mutant” types of p53 and interactions with other proteins that delineate hundreds, if not thousands, of pathways that companies are researching. But, to the best of our knowledge, no one has collected the type of extremely promising data with their compound that we have. As biotechnology researchers, we – as well as all the other experts that have looked at Kevetrin’s data – have to be chronic cynics. That is what has driven us to test Kevetrin so extensively before heading into clinical trials. The data collected coupled with the responses that we have received from some of the brightest minds in oncology is what keeps our confidence level high at this point.